Hsu C, Yeh K H, Hong R L, Yang C H, Lin M T, Chen Y C, Cheng A L
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.
J Formos Med Assoc. 1997 Mar;96(3):185-8.
Salvage chemotherapy for relapsed and refractory metastatic breast cancer is a challenging issue for oncologists. At our institution, the combination of mitomycin-C, vinblastine and cisplatin (MVP) is used for treatment. The records of 19 consecutive patients with refractory metastatic breast cancer treated with MVP between April 1992 and October 1995 were reviewed. The regimen consisted of mitomycin-C 6 mg/m2, vinblastine 6 mg/m2 and cisplatin 60 mg/m2, repeated every 3 to 4 weeks. The median age of patients was 49 years (range, 35-71 yr). All patients had clinically measurable or evaluable disease and a Karnofsky's performance status greater than or equal to 50%. The median number of prior chemotherapy regimens was two (range, 1-4). Eighteen (94.7%) patients had previously received an anthracycline/anthracenedione-containing regimen, and seven (36.9%) had progression of disease during these therapies. Sixteen patients had two or more sites of metastasis and 17 patients had visceral disease. The median duration of follow-up was 26 months. A mean of 3.5 courses (range, 1-7) was administered. One patient was lost to follow-up after one course of treatment. Of the remaining 18 patients, two complete and five partial responses were observed, for a total response rate of 37% (range, 17-61%, 95% CI). One of the partial responders had disease progression during anthracycline treatment. Treatment-related toxicities were relatively well tolerated. There were no treatment-related deaths. The median duration of response was 3 months (range, 2-11 mo). The median overall survival was 7 months (range, 1-32 mo). Our data suggest that the MVP regimen is an effective palliative treatment for patients with refractory metastatic breast cancer.
对于复发和难治性转移性乳腺癌患者，挽救性化疗是肿瘤学家面临的一个具有挑战性的问题。在我们机构，丝裂霉素-C、长春碱和顺铂（MVP）联合方案用于治疗。回顾了1992年4月至1995年10月期间连续19例接受MVP治疗的难治性转移性乳腺癌患者的记录。该方案包括丝裂霉素-C 6mg/m²、长春碱6mg/m²和顺铂60mg/m²，每3至4周重复一次。患者的中位年龄为49岁（范围35 - 71岁）。所有患者均有临床可测量或可评估的疾病，且卡氏评分大于或等于50%。既往化疗方案的中位数为2种（范围1 - 4种）。18例（94.7%）患者既往接受过含蒽环类/蒽二酮类的方案，其中7例（36.9%）在这些治疗期间疾病进展。16例患者有两个或更多转移部位，17例患者有内脏疾病。中位随访时间为26个月。平均给予3.5个疗程（范围1 - 7个疗程）。1例患者在接受1个疗程治疗后失访。在其余18例患者中，观察到2例完全缓解和5例部分缓解，总缓解率为37%（范围17% - 61%，95%CI）。其中1例部分缓解者在蒽环类治疗期间疾病进展。治疗相关毒性相对耐受良好。无治疗相关死亡。中位缓解持续时间为3个月（范围2 - 11个月）。中位总生存期为7个月（范围1 - 32个月）。我们的数据表明，MVP方案是难治性转移性乳腺癌患者有效的姑息治疗方案。
